1,106 Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Collaborative Fund Advisors LLC

Collaborative Fund Advisors LLC lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 106.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,142 shares of the pharmaceutical company’s stock after buying an additional 1,106 shares during the quarter. Collaborative Fund Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $1,120,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of VRTX. Summit Global Investments acquired a new stake in Vertex Pharmaceuticals during the second quarter worth about $3,568,000. Calamos Advisors LLC increased its position in shares of Vertex Pharmaceuticals by 77.1% in the first quarter. Calamos Advisors LLC now owns 77,886 shares of the pharmaceutical company’s stock worth $34,779,000 after acquiring an additional 33,917 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter worth $13,823,000. UNIVEST FINANCIAL Corp acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter worth $4,495,000. Finally, Meeder Advisory Services Inc. purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $3,187,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported third-quarter revenue of $3.44 billion, up 12% year over year and ahead of estimates, with cystic fibrosis medicines and newer products including CASGEVY and JOURNAVX contributing. The company raised its 2026 revenue outlook, while management highlighted the potential for povetacicept, which faces an FDA decision for IgA nephropathy on November 30. Vertex Q3 2026 earnings call highlights
• Positive Sentiment: Analyst actions have generally been supportive: Barclays raised its price target to $626 and kept an overweight rating, while H.C. Wainwright reiterated Buy and TD Cowen also rated the shares Buy. These endorsements may bolster confidence in Vertex’s growth prospects.
• Neutral Sentiment: Investors are also focused on Vertex’s efforts to expand beyond cystic fibrosis into kidney and rare endocrine diseases—potential future growth drivers, but ones that will take time to establish. Vertex: 3 key takeaways for long-term investors
• Negative Sentiment: Quarterly earnings per share came in below analyst expectations, and acquisition costs weighed on profit. Reports also pointed to lighter-than-hoped-for sales of the pain drug JOURNAVX, contributing to a selloff after the earnings release. Vertex slumps on light pain drug sales

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on VRTX shares. Wall Street Zen lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, October 31st. Daiwa Securities Group raised their target price on Vertex Pharmaceuticals from $555.00 to $556.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Morgan Stanley reduced their price target on Vertex Pharmaceuticals from $665.00 to $660.00 and set an “overweight” rating on the stock in a research report on Tuesday. Scotiabank upped their price target on Vertex Pharmaceuticals from $558.00 to $660.00 and gave the stock a “sector outperform” rating in a report on Tuesday. Finally, Sanford C. Bernstein raised shares of Vertex Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $596.44.

Vertex Pharmaceuticals Stock Up 3.4%

Vertex Pharmaceuticals stock opened at $549.04 on Thursday. Vertex Pharmaceuticals Incorporated has a 52 week low of $406.67 and a 52 week high of $568.67. The stock has a market cap of $139.35 billion, a price-to-earnings ratio of 35.33, a PEG ratio of 2.56 and a beta of 0.28. The company’s 50-day moving average price is $522.90 and its two-hundred day moving average price is $480.92. The company has a current ratio of 2.34, a quick ratio of 2.74 and a debt-to-equity ratio of 0.17.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.06). The company had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.42 billion. Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The company’s revenue was up 11.8% on a year-over-year basis. During the same quarter last year, the business earned $4.80 earnings per share. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post 16.64 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.